MedTrace Logo

DNA Chip Based Prognosis of Lung Cancer

NCT00973427 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2015-09-23

No results posted yet for this study

Summary

The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

  • Medical Prognosis Institute A/S

    lead INDUSTRY

Principal Investigators

  • Steen Knudsen, PhD · Medical Prognosis Institute (MPI)

  • Jens B. Sørensen, MD · Dept. Oncology, Copenhagen University

  • Jesper Ravn, MD · University of Copenhagen

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States
  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973427 on ClinicalTrials.gov